|
Delayed
OTC Markets
15:51:37 12/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 163.68 USD | +0.76% |
|
+1.75% | +17.12% |
| 11-09 | UCB Announces Week 24 Data For BIMZELX Bimekizumab-Bkzx From BE BOLD Study | CI |
| 11-09 | UCB And Biogen Announce Clinical Profile Data For Dapirolizumab Pegol In Systemic Lupus Erythematosus | CI |
| Market Cap | 55.54B 61.62B 51.31B 46.39B 87.76B 5,780B 89.93B 615B 245B 3,095B 231B 226B 9,850B | P/E 2026 * |
24.8x | P/E 2027 * | 21.6x |
|---|---|---|---|---|---|
| Enterprise Value | 55.66B 61.76B 51.42B 46.49B 87.95B 5,792B 90.12B 616B 246B 3,102B 232B 227B 9,872B | EV / Sales 2026 * |
6.15x | EV / Sales 2027 * | 5.31x |
| Free-Float |
61.59% | Yield 2026 * |
0.5% | Yield 2027 * | 0.52% |
| Markets | Quality | ||
|---|---|---|---|
OTC Markets
| UCBJY | Delayed | |
Deutsche Boerse AG
| UNC0 | Delayed | |
|
Börse Stuttgart
| UNC0 | Delayed |
Last Transcript: UCB SA
| 1 day | +0.76% | ||
| 1 week | +1.75% | ||
| Current month | +4.39% | ||
| 1 month | +43.63% | ||
| 3 months | +28.09% | ||
| 6 months | +15.86% | ||
| Current year | +17.12% |
| 1 week | 158.52 |  | 168.64 |
| 1 month | 110.55 | | 168.64 |
| Current year | 110.55 | | 168.76 |
| 1 year | 110.55 | | 168.76 |
| 3 years | 34.85 | | 168.76 |
| 5 years | 32.82 | | 168.76 |
| 10 years | 29.2 | | 168.76 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 31/12/2014 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 30/06/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 30/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 31/12/2011 | |
| Director/Board Member | 67 | 31/12/2014 | |
| Director/Board Member | 56 | 23/04/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.76% | +1.75% | - | - | 61.62B | |
| +0.65% | +5.99% | +42.12% | +136.08% | 1,280B | |
| +1.06% | +4.07% | +45.79% | +91.97% | 675B | |
| +0.48% | +2.95% | +27.23% | +114.04% | 521B | |
| +1.27% | +3.93% | +40.19% | +70.51% | 386B | |
| +0.32% | +0.50% | +61.49% | +44.12% | 363B | |
| +1.07% | +0.10% | +28.23% | +58.66% | 301B | |
| +0.38% | -0.54% | +3.31% | +36.28% | 286B | |
| +0.53% | +2.25% | +39.96% | +76.48% | 253B | |
| +0.36% | +1.77% | +38.19% | +127.59% | 211B | |
| Average | +0.68% | -0.51% | +36.28% | +83.97% | 475B | |
| Weighted average by Cap. | +0.71% | +0.20% | +38.46% | +96.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.05B 10.04B 8.36B 7.56B 14.3B 942B 14.66B 100B 39.94B 504B 37.69B 36.89B 1,605B | 10.05B 11.15B 9.28B 8.39B 15.88B 1,046B 16.27B 111B 44.35B 560B 41.84B 40.95B 1,782B |
| Net income | 2.27B 2.52B 2.1B 1.9B 3.59B 237B 3.68B 25.17B 10.03B 127B 9.46B 9.26B 403B | 2.59B 2.87B 2.39B 2.16B 4.09B 270B 4.19B 28.68B 11.43B 144B 10.78B 10.56B 459B |
| Net Debt | 122M 135M 113M 102M 193M 12.68B 197M 1.35B 538M 6.79B 508M 497M 21.62B | -2.21B -2.46B -2.05B -1.85B -3.5B -230B -3.58B -24.51B -9.77B -123B -9.22B -9.02B -393B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/11/26 | US$163.68 | +0.76% | 6,092 |
| 11/11/26 | US$162.45 | -1.71% | 12,119 |
| 10/11/26 | US$165.27 | -1.48% | 14,563 |
| 09/11/26 | US$167.76 | +3.63% | 35,388 |
| 06/11/26 | US$161.88 | +0.63% | 21,233 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
- UCBJY Stock
Select your edition
All financial news and data tailored to specific country editions
